Health and Healthcare Systems

Everything you need to know about the G7’s plan to donate 1 billion vaccine doses

A picture of the G7 leaders with Queen Elizabeth II, including European Commission President Ursula von der Leyen, German Chancellor Angela Merkel, Japan's Prime Minister Yoshihide Suga, France's President Emmanuel Macron along with Britain's Queen Elizabeth, Canada's Prime Minister Justin Trudeau, Britain's Prime Minister Boris Johnson, Italy's Prime Minister Mario Draghi, U.S. President Joe Biden and European Council President Charles Michel

The G7 plan to donate a billion COVID-19 vaccine doses to poorer countries. Image: REUTERS

Andrea Shalal
Senior Correspondent, Reuters
Allison Martell
Author, Reuters
Carl O'Donnell
Reporter , Reuters
  • The G7 have announced their plan to donate a billion COVID-19 vaccine doses to poorer countries.
  • However, some experts fear it offers only a small lifeline to the global vaccine buying system.
  • The donation is far short of the 5 billion to 6 billion shots needed by poorer nations, and it does not address distribution gaps.
  • Many of the promised doses will flow through COVAX, a global vaccine buying system backed by the World Health Organization and Gavi.
  • It is still a much-needed boost to the facility, which has only distributed 83 million shots worldwide.

A G7 plan to donate a billion COVID-19 vaccine doses to poorer countries will have limited impact because it includes some previous pledges, but it still offers a small lifeline to a global vaccine buying system, according to some experts.

Leaders from the Group of Seven major economies announced the move on Friday. A U.S. initiative announced on Thursday to donate 500 million doses of the Pfizer (PFE.N) and BioNTech SE (22UAy.DE) vaccine is part of the G7 pledge.

Have you read?

Many of the promised doses will flow through COVAX, a global vaccine buying system backed by the World Health Organization and Gavi, the vaccine alliance.

The pledge does not represent entirely new resources, and the donation is far short of the 5 billion to 6 billion shots needed by poorer nations. Moreover, the plan does not address distribution gaps that could make it difficult to deliver doses.

COVID-19 vaccine doses administered by country income group
COVID-19 vaccine doses administered by country income group Image: Our World in Data

But experts said it is still a much-needed boost to COVAX, which has so far only distributed 83 million shots worldwide.

COVAX has struggled to secure deliveries as wealthy nations reserve enough shots to vaccinate their populations several times over.

"It's going to rescue COVAX from its pretty dire predicament right now, so it's a very significant step," said Stephen Morrison, the director of the Global Health Policy Center at the Center for Strategic and International Studies, a think tank.

The United Kingdom's 100 million dose pledge is "entirely new" according to a spokesperson. But the European Union's 100 million dose commitment was promised during a summit in May, and the U.S. commitment partially replaces earlier promises to fund COVAX directly.

The United States has already donated $2 billion to COVAX, according to a White House official. In February, the Biden administration pledged $2 billion more. But that second $2 billion will now fund the purchase of the Pfizer doses, along with $1.5 billion in additional funds, according to the official.

Even if the shots are acquired and shipped, they risk overwhelming developing countries' limited distribution infrastructure, especially if many are delivered together late this year.

Discover

What is the World Economic Forum doing about access to vaccines?

The World Bank extended a $12 billion line of credit for developing countries to build out vaccine distribution infrastructure, but governments have drawn down only about $3 billion.

"The low-income countries are wary of increasing their debt profile, that is the reality," said Edwin Ikhuoria, executive director for the ONE Campaign, a nonprofit focused on poverty and public health.

Others argue that wealthy countries should find a way to ship doses more quickly, especially as some near expiry in countries with high vaccination rates, including those made by Johnson & Johnson Inc (JNJ.N).

“When you just see the graph of the increase of vaccination coverage in wealthy countries and the accelerated pace at which that has been happening, and then when you look at the pace in developing countries, it’s just so stark,” said Kate Elder, senior vaccines policy adviser at Médecins Sans Frontières. “Doses are needed now.”

Loading...
Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Stay up to date:

COVID-19

Related topics:
Health and Healthcare SystemsGeo-Economics and Politics
Share:
The Big Picture
Explore and monitor how COVID-19 is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

COPD kills more than lung and breast cancer combined. It's time to change that

Nitin Kapoor

November 22, 2024

A historic leap in cancer vaccines – here’s what you need to know

About us

Engage with us

  • Sign in
  • Partner with us
  • Become a member
  • Sign up for our press releases
  • Subscribe to our newsletters
  • Contact us

Quick links

Language editions

Privacy Policy & Terms of Service

Sitemap

© 2024 World Economic Forum